𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities

✍ Scribed by J. M. Klaase; B. B. R. Kroon; C. Benckhuijsen; A. N. van Geel; Ch. E. Albus-Lutter; J. Wieberdink

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
712 KB
Volume
64
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Isolated limb perfusion with tumor necro
Isolated limb perfusion with tumor necrosis factor-Ξ± and melphalan for patients with unresectable soft tissue sarcoma of the extremities
✍ Eva M. Noorda; Bart C. Vrouenraets; Omgo E. Nieweg; Frits van Coevorden; Gooike πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 90 KB

## Abstract ## BACKGROUND Since 1992, isolated limb perfusion (ILP) with tumor necrosis factor‐α (TNFΞ±) and melphalan has been used for the treatment of patients with unresectable soft tissue sarcomas of the extremities. The authors retrospectively studied the results of limb salvage surgery using

Adjuvant regional isolated perfusion wit
Adjuvant regional isolated perfusion with melphalan for patients with clark V melanoma of the extremities
✍ Bart C. Vrouenraets; Dr. Bin B. R. Kroon; Joost M. Klaase; Bert N. Van Gell; Ale πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 419 KB

From 1978 to 1990, 32 patients with Clark V melanoma were treated by wide excision of the primary and adjuvant regional isolated perfusion with melphalan. M.D. Anderson stage of disease was stage I in 22 and stage IIIb in 10 patients. Five-year survival rates were 58% and 27%, respectively. Seven pa

Pharmacokinetics of dacarbazine in the r
Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma
✍ Didolkar, Mukund S.; Jackson, Andre J.; Lesko, Lawrence J.; Fitzpatrick, J. Lawr πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 811 KB

## Background: The pharmacokinetics of dacarbazine (DTIC), which has been shown to be an effective therapeutic agent against metastatic melanoma, has not been extensively studied. However, to improve the clinical use of the drug, more information on the kinetics is required. Methods: A pharmacokine